AU2021270426A1 - Novel inhalant - Google Patents

Novel inhalant Download PDF

Info

Publication number
AU2021270426A1
AU2021270426A1 AU2021270426A AU2021270426A AU2021270426A1 AU 2021270426 A1 AU2021270426 A1 AU 2021270426A1 AU 2021270426 A AU2021270426 A AU 2021270426A AU 2021270426 A AU2021270426 A AU 2021270426A AU 2021270426 A1 AU2021270426 A1 AU 2021270426A1
Authority
AU
Australia
Prior art keywords
cepharanthine
inhalant
inhalation
powder
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021270426A
Other languages
English (en)
Inventor
Seiichi Murakami
Mutsuo Okumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of AU2021270426A1 publication Critical patent/AU2021270426A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021270426A 2020-05-14 2021-05-14 Novel inhalant Abandoned AU2021270426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020085471 2020-05-14
JP2020-085471 2020-05-14
PCT/JP2021/018328 WO2021230340A1 (ja) 2020-05-14 2021-05-14 新規吸入剤

Publications (1)

Publication Number Publication Date
AU2021270426A1 true AU2021270426A1 (en) 2022-12-08

Family

ID=78524492

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021270426A Abandoned AU2021270426A1 (en) 2020-05-14 2021-05-14 Novel inhalant

Country Status (8)

Country Link
US (1) US20230338365A1 (https=)
EP (1) EP4151211A1 (https=)
JP (1) JPWO2021230340A1 (https=)
KR (1) KR20230011282A (https=)
CN (1) CN117083063A (https=)
AU (1) AU2021270426A1 (https=)
PH (1) PH12022553084A1 (https=)
WO (1) WO2021230340A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
JP2024178477A (ja) * 2021-11-04 2024-12-25 興和株式会社 カプセル剤
JP2024178478A (ja) * 2021-11-04 2024-12-25 興和株式会社 医薬品
CN118555958A (zh) * 2021-11-17 2024-08-27 国立感染症研究所所长代表的日本国 含有来自金线吊乌龟的生物碱的制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1201737C (zh) * 2003-06-19 2005-05-18 广州暨南生物医药研究开发基地有限公司 千金藤素在制备抗sars病毒药物中的应用
WO2007011396A2 (en) * 2004-10-29 2007-01-25 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
CN1771953A (zh) * 2005-11-01 2006-05-17 袁继民 一种含有千金藤素的药物
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
CN110151691A (zh) * 2019-06-19 2019-08-23 宁夏医科大学 一种千金藤素纳米混悬液及其制备方法

Also Published As

Publication number Publication date
WO2021230340A1 (ja) 2021-11-18
CN117083063A (zh) 2023-11-17
JPWO2021230340A1 (https=) 2021-11-18
US20230338365A1 (en) 2023-10-26
EP4151211A1 (en) 2023-03-22
KR20230011282A (ko) 2023-01-20
PH12022553084A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
AU2021270426A1 (en) Novel inhalant
US6080762A (en) Pulmonary and nasal delivery of raloxifene
TWI758617B (zh) 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途
US20130064870A1 (en) Dry powder inhalation composition
TR201802921T4 (tr) Bir muskarinik reseptör antagonistinin ve bir beta-2 adrenoreseptör agonistinin kombinasyonları.
EP3932400B1 (en) Peramivir solution type inhalant and preparation method therefor
JP2002532405A (ja) オピオイド吸入製剤
EP2957553A1 (en) Pharmaceutical formulations of vilanterol
EP2957552B1 (en) Vilanterol formulations
US6462090B1 (en) Formulations for detecting asthma
JP2024049405A (ja) 新規吸入剤
EP2957551B1 (en) Dry powder formulations comprising vilanterol
AU2020356243B2 (en) Novel carrier particles for dry powder formulations for inhalation
JP2024125434A (ja) 新規吸入剤
CN116196298A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
WO2023068287A1 (ja) 新規医薬
EP3390423A1 (en) Polymorphic forms and process
KR20180030399A (ko) 네뷸라이저용 조성물
CN114073684A (zh) 三苯乙酸维兰特罗吸入溶液及其制备方法
CZ20003544A3 (cs) Pulmonární a nasální podávání raloxifenu
EP2957550A1 (en) Pharmaceutical formulations comprising vilanterol

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period